DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR HEPARIN SODIUM 12,500 UNITS IN SODIUM CHLORIDE 0.9%
Clinical Trials for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
| Trial ID | Title | Status | Sponsor | Phase | Summary |
|---|---|---|---|---|---|
| NCT00000468 | Myocardial Infarction Triage and Intervention Project (MITI) | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy. |
| NCT00000468 | Myocardial Infarction Triage and Intervention Project (MITI) | Completed | University of Washington | Phase 3 | To determine the practicality, benefit, and safety of paramedic administration of thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly identifying candidates for thrombolytic therapy following myocardial infarction was assessed in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital thrombolytic therapy. |
| NCT00182143 | PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) | Completed | Australian and New Zealand Intensive Care Society Clinical Trials Group | Phase 3 | The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site. |
| NCT00182143 | PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) | Completed | Canadian Critical Care Trials Group | Phase 3 | The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site. |
| NCT00182143 | PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) | Completed | Canadian Institutes of Health Research (CIHR) | Phase 3 | The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site. |
| NCT00182143 | PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT) | Completed | McMaster University | Phase 3 | The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH) (Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and objectively confirmed venous thrombosis at any site. |
| NCT00203580 | Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study) | Completed | Canadian Institutes of Health Research (CIHR) | Phase 4 | The purpose of this study is to assess the long-term treatment of patients with proximal venous thrombosis through the administration of subcutaneous low-molecular-weight heparin (tinzaparin sodium) versus the standard care use of intravenous heparin followed by oral warfarin sodium. |
| Trial ID | Title | Status | Sponsor | Phase | Summary |
Clinical Trial Conditions for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Clinical Trial Locations for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Trials by Country
Clinical Trial Progress for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Clinical Trial Sponsors for Heparin Sodium 12,500 Units In Sodium Chloride 0.9%
Sponsor Name
